CA2858571C - Composition and method for neuropeptide s receptor (npsr) antagonists - Google Patents
Composition and method for neuropeptide s receptor (npsr) antagonists Download PDFInfo
- Publication number
- CA2858571C CA2858571C CA2858571A CA2858571A CA2858571C CA 2858571 C CA2858571 C CA 2858571C CA 2858571 A CA2858571 A CA 2858571A CA 2858571 A CA2858571 A CA 2858571A CA 2858571 C CA2858571 C CA 2858571C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- mmol
- nps
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Addiction (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161568540P | 2011-12-08 | 2011-12-08 | |
| US61/568,540 | 2011-12-08 | ||
| PCT/US2012/068257 WO2013086200A1 (en) | 2011-12-08 | 2012-12-06 | Composition and method for neuropeptide s receptor (npsr) antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2858571A1 CA2858571A1 (en) | 2013-06-13 |
| CA2858571C true CA2858571C (en) | 2021-03-16 |
Family
ID=48574884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2858571A Active CA2858571C (en) | 2011-12-08 | 2012-12-06 | Composition and method for neuropeptide s receptor (npsr) antagonists |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9150582B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2788359B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6381445B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012347758B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2858571C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2624853T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013086200A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017246706B2 (en) * | 2016-04-04 | 2020-09-17 | Research Triangle Institute | Neuropeptide s receptor (NPSR) agonists |
| JOP20190060A1 (ar) * | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4917489B1 (cg-RX-API-DMAC7.html) * | 1970-01-22 | 1974-05-01 | ||
| EP0140833B1 (de) * | 1983-09-15 | 1988-03-02 | Ciba-Geigy Ag | 5-und 6-Azaphthalide, ihre Isomerengemische, Verfahren zu ihrer Herstellung und ihre Verwendung in druck- und wärmeempfindlichen Aufzeichnungsmaterialien |
| EP0558521A1 (en) * | 1990-11-22 | 1993-09-08 | Janssen Pharmaceutica N.V. | Isonicotinic acid derivatives and related spiro compounds with herbicidal action |
| EP1329508B1 (en) | 2000-10-13 | 2010-09-08 | Takeda Pharmaceutical Company Limited | Novel g protein-coupled receptor protein and dna thereof |
| US6642255B2 (en) * | 2001-01-11 | 2003-11-04 | Bristol-Myers Squibb Pharma Company | 1,2,-Disubstituted cyclic inhibitors of matrix metalloproteases and TNF-alpha |
| US9012407B2 (en) * | 2004-04-23 | 2015-04-21 | The Regents Of The University Of California | Therapies which act on neuropeptide S receptors |
| EP2365748A4 (en) * | 2008-11-13 | 2012-05-02 | Merck Sharp & Dohme | IMIDAZOISOINDOL neuropeptide S RECEPTOR ANTAGONISTS |
| EP2365749A4 (en) * | 2008-11-13 | 2012-05-30 | Merck Sharp & Dohme | Quinolone NEURO PEPTIDE-S-Receptor Antagonists |
-
2012
- 2012-12-06 EP EP12854821.1A patent/EP2788359B1/en active Active
- 2012-12-06 ES ES12854821.1T patent/ES2624853T3/es active Active
- 2012-12-06 JP JP2014546080A patent/JP6381445B2/ja active Active
- 2012-12-06 WO PCT/US2012/068257 patent/WO2013086200A1/en not_active Ceased
- 2012-12-06 US US14/363,079 patent/US9150582B2/en active Active
- 2012-12-06 CA CA2858571A patent/CA2858571C/en active Active
- 2012-12-06 AU AU2012347758A patent/AU2012347758B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2788359A4 (en) | 2015-06-10 |
| AU2012347758A1 (en) | 2014-06-05 |
| US9150582B2 (en) | 2015-10-06 |
| AU2012347758B2 (en) | 2017-01-19 |
| JP2015500293A (ja) | 2015-01-05 |
| CA2858571A1 (en) | 2013-06-13 |
| WO2013086200A1 (en) | 2013-06-13 |
| ES2624853T3 (es) | 2017-07-17 |
| EP2788359A1 (en) | 2014-10-15 |
| US20150057268A1 (en) | 2015-02-26 |
| EP2788359B1 (en) | 2017-03-01 |
| JP6381445B2 (ja) | 2018-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102038161B1 (ko) | Nmda 수용체 조절물질 및 그의 용도 | |
| KR101769999B1 (ko) | Nmda 수용체 조절제 및 그의 용도 | |
| US6410548B2 (en) | Spiropiperidine derivatives as melanocortin receptor agonists | |
| AU742425B2 (en) | Spiropiperidine derivatives as melanocortin receptor agonists | |
| CN102153562B (zh) | 螺-吲哚酮化合物及其作为治疗剂的用途 | |
| ES2308839T3 (es) | Amidas n,n-disustituidas que inhiben la union de integrinas a sus receptores. | |
| RU2572818C2 (ru) | Производное тетрагидрокарболина | |
| KR20060058104A (ko) | 벤즈아미드 치환체를 갖는 사이클릭 아민 bace-1억제제 | |
| AU2013230425A1 (en) | Substituted heterocyclic acetamides as kappa opioid receptor (kor) agonists | |
| KR20140129065A (ko) | 축합 피롤디카복사미드 및 약제로서의 그의 용도 | |
| TW201321384A (zh) | 作為鈣通道阻斷劑之經取代之八氫吡咯并[1,2-a]吡□磺醯胺 | |
| EP1301516A1 (en) | Modulators of protein tyrosine phosphatases (ptpases) | |
| AU2012347758B2 (en) | Composition and method for neuropeptide S receptor (NPSR) antagonists | |
| NO844560L (no) | Nye amidforbindelser. | |
| EP1797065A2 (en) | Acyclic 1,3-diamines and uses therefor | |
| KR20010083109A (ko) | 아미노산 유도체 및 이들을 유효 성분으로서 함유하는 약제 | |
| CA3018344C (en) | Neuropeptide s receptor (npsr) agonists | |
| RU2792034C2 (ru) | Тетрагидроизохинолиновое соединение, способ его получения, фармацевтическая композиция, содержащая такое соединение, и его применение | |
| JP2014512384A (ja) | ジアゾナミドアナログ | |
| CA3018344A1 (en) | Neuropeptide s receptor (npsr) agonists | |
| HK1168104B (en) | Spiro-oxindole compounds and their uses as therapeutic agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20171110 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD Year of fee payment: 12 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241115 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241115 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251120 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251120 |